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Background: Controlled human malaria infection (CHMI) studies increasingly rely on nucleic acid test (NAT) methods to
detect and quantify parasites in the blood of infected participants. The lower limits of detection and quantification vary
amongst the assays used throughout the world, which may affect the ability of mathematical models to accurately
estimate the liver-to-blood inoculum (LBI) values that are used to judge the efficacy of pre-erythrocytic vaccine and drug
candidates.
Methods: Samples were collected around the time of onset of pre-patent parasitaemia from subjects who enrolled in
two different CHMI clinical trials. Blood samples were tested for Plasmodium falciparum 18S rRNA and/or rDNA targets by
different NAT methods and results were compared. Methods included an ultrasensitive, large volume modification of an
established quantitative reverse transcription PCR (qRT-PCR) assay that achieves detection of as little as one parasite/mL of
whole blood.
Results: Large volume qRT-PCR at the University of Washington was the most sensitive test and generated quantifiable
data more often than any other NAT methodology. Standard quantitative PCR (qPCR) performed at the University of
Oxford and standard volume qRT-PCR performed at the University of Washington were less sensitive than the large
volume qRT-PCR, especially at 6.5 days after CHMI. In these trials, the proportion of participants for whom LBI could be
accurately quantified using parasite density value greater than or equal to the lower limit of quantification was increased.
A greater improvement would be expected in trials in which numerous subjects receive a lower LBI or low dose
challenge.
Conclusions: Standard qPCR and qRT-PCR methods with analytical sensitivities of ~20 parasites/mL probably suffice for
most CHMI purposes, but the newly developed large volume qRT-PCR may be able to answer specific questions when
more analytical sensitivity is required.
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The controlled human malaria infection (CHMI) model is
a well-established system to determine the efficacy of drug
and vaccine candidates early in their clinical development
process. In this model, healthy human subjects are infected
with Plasmodium spp. either through the bite of infectious
mosquitoes or by needle-based administration of cryopre-
served sporozoites or infected red blood cells [1-4]. Upon
diagnosis of patent parasitaemia by thick blood smear
(TBS), or in some cases pre-patent parasitaemia by nucleic
acid tests (NATs), subjects are treated with approved cura-
tive therapy and followed to ensure parasite clearance and
recovery.
Various NATs have been used to detect and quantify pre-
microscopy patent blood-stage parasitaemia. The most
common targets are the 18S rRNA-coding genes (rDNA)
or the asexual-type 18S rRNAs themselves, which can be
detected by nested polymerase chain reaction (PCR), quan-
titative PCR (qPCR), nucleic acid sequence-based amplifica-
tion (NASBA) and quantitative reverse transcription PCR
(qRT-PCR), as recently reviewed [5]. When applied in the
post-CHMI setting, blood-stage infections can often be de-
tected by NATs two to five days earlier than by TBS, with
highly sensitive NAT assays becoming positive around Day
7 post-CHMI (D7.0) when standard CHMI doses of five in-
fectious mosquito bites are used [6-10].
Modelling of NAT data allows calculation of the parasite
multiplication rate (PMR) of blood-stage parasites as well as
estimation of the number of parasites released from the liver
into the blood (liver-to-blood inoculum (LBI)) [11]. LBI is a
measure of the efficacy of drugs and vaccines designed to re-
duce or eliminate liver-stage development of the pre-
erythrocytic malaria parasite. Parasite release from the liver
after CHMI is thought to start on D6 but not be complete
until D7.5 [12,13]; one report indicated detection as early as
D5 post-CHMI [10]. Since many samples are NAT negative
at these early timepoints, direct measurement of LBI is not
possible so modelling methods are usually employed to esti-
mate LBI [11]. If it were possible to enhance NAT sensitivity
at these early timepoints to allow direct measurement of
LBI, the accuracy and confidence of LBI measures would be
markedly increased.
Each ring-stage parasite genome contains five 18S
rDNA genes, and DNA-based NATs can therefore detect
1–5 of those copies depending on sequence specificity. At
the published 5 parasites/mL (p/mL) lower limit of detec-
tion (LLD) for the Oxford qPCR method [9], 15 copies of
the Oxford assay’s target sequence are present in 1 mL of
whole blood (three copies per parasite genome). For this
assay, the LLD is the lowest target density where rDNA
from the 0.5 mL whole blood extraction is likely to be
present in the 10% eluate volume transferred into each
qPCR reaction, resulting in a just-detectable qPCR signal
with a cycle threshold (CT) of ~41 cycles. Because of thelow number of target sequences per parasite, this LLD is
somewhat higher than the parasite density at which it be-
comes probable that at least one parasite will be present in
the blood from which DNA is extracted. The lower limit of
quantification (LLQ) is yet again higher than the LLD.
In contrast, in the University of Washington (UW) qRT-
PCR method [14], ~3,500 target 18S rRNA copies are
present per ring-stage parasite. At the 20 p/mL published
LLD, the quanta of rRNA for a single parasite in 0.05 mL of
whole blood leads to qRT-PCR detection at a CT of ~33.5 cy-
cles. Thus, in qRT-PCR, the sample volume is the primary
limiting factor for the LLD since each parasite contains a
readily-detectable number of targets. Since the rRNA is ~3
logs more abundant than the parent rDNA genes, qRT-PCR
can be performed on small blood volumes and yet achieve
sensitivities comparable to that of larger volume qPCR.
With these issues in mind, assay modifications were tested
in an attempt to increase the sensitivity of qPCR and qRT-
PCR to directly measure LBI on D6 post-CHMI.
To increase the sensitivity of Oxford qPCR to detect
infections at <5 p/mL, larger volumes of blood could be
processed and/or a larger proportion of extracted DNA
could be used per PCR reaction. In either case, enhanced
sensitivity would require maintenance of a reasonable
ratio of parasite DNA to blood-derived PCR inhibitors –
adequate removal of human DNA and other PCR inhibi-
tors such as haemoglobin from large samples can be
challenging (ADD, unpublished observations). Because
of the low number of target copies per parasite, this
problem cannot be overcome readily by diluting the ex-
tracted DNA. In addition, it is relatively inconvenient to
collect, store and process 5–10 mL volumes of whole
blood for PCR-based diagnostics.
To enhance the analytical sensitivity of qRT-PCR to
detect infections at <20 p/mL, a ten-fold larger sample
could be collected (0.5 mL vs 0.05 mL) provided that it
was preserved in ten-fold more lysis buffer (20 mL vs
2 mL). With this approach, the LLD could theoretically
reach 2 p/mL. If a 0.5 mL blood aliquot contained a sin-
gle parasite with ~3,500 target copies, ~170 rRNA copies
would be aliquoted into the qRT-PCR reaction as com-
pared to only 2–5 rDNA copies. Here, this approach was
tested using duplicate 0.5 mL qRT-PCR samples (here-
after referred to as ‘large volume’ qRT-PCR) alongside
other approaches including the 0.5 mL Oxford qPCR
method, the standard 0.05 mL qRT-PCR method and a




Whole blood samples were obtained from subjects en-
rolled in two Institutional Review Board-approved CHMI
trials: VAC052 and KCS.
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Clinical Vaccinology & Tropical Medicine, Oxford, UK to
assess the efficacy of candidate pre-erythrocytic viral vectors
chimpanzee adenovirus 63 (ChAd63) and modified vaccinia
virus Ankara (MVA) vectors containing multiple epitopes -
thrombospondin related adhesion protein (ME-TRAP), cir-
cumsporozoite protein (CS) and apical membrane antigen 1
(AMA1) administered in combination (Clinicaltrials.gov
NCT01739036) (NAA et al., in preparation). The study con-
sisted of three groups: Group 1 immunized with ChAd63-
MVA ME-TRAP+CSP (n = 13), Group 2 immunized
with ChAd63-MVA ME-TRAP+CSP +AMA1 (n = 13) and
Group 3 unimmunized infectivity controls (n = 6). Volun-
teers underwent CHMI with five Plasmodium falciparum-
infected (3D7) mosquito bites. Sporozoite carriage was con-
firmed by dissection and microscopy following blood meals
and each mosquito was required to display evidence of a
blood meal and ≥11 sporozoites in its salivary glands.
VAC052 was approved by the National Research Ethics
Service Committee South Central – Oxford A, UK and the
Western Institutional Review Board, USA. The study was
conducted from January to October 2013.
The KCS study was a CHMI trial conducted at the
Kenyan Medical Research Institute (KEMRI) Centre for
Clinical Research, Nairobi, Kenya (Pan African Clinical
Trial Registry PACTR20121100033272) [15]. Volunteers
with varying degrees of prior exposure to malaria were
infected using intramuscular administration of different
doses of aseptic, purified, cryopreserved P. falciparum
(NF54) sporozoites (PfSPZ Challenge, Sanaria, Inc.)
[8,9,16]. The KCS study was approved by KEMRI Ethics
Review Committee, Kenya and the Oxford Tropical Re-
search Ethics Committee, UK and was conducted under
a US Food and Drug Administration Investigational
New Drug Application (FDA IND #14267). The study
was conducted from March to August 2013.
In both studies, CHMI occurred on D0. For VAC052,
Oxford qPCR assay and TBS microscopy were performed at
D6.5, D7.0, D7.3, and D7.5, twice daily from D8.0 until
D14.0 and once daily from D15.0 to D21.0, at which point
all undiagnosed volunteers were treated. Matched samples
for qRT-PCR were obtained at D7.5 only. For KCS, Oxford
qPCR and TBS were performed at D6.5, twice daily from
D7.0 until D14.0 and once daily from D15.0 to D21.0, at
which point all undiagnosed volunteers were treated.
Matched samples for qRT-PCR were obtained at D6.5, D7.0
and D7.5. TBS was performed as described [15].
Sample preparation
EDTA-anticoagulated whole blood was collected on the
indicated days following CHMI. For the Oxford qPCR
assay, 2 mL of whole blood was filtered to remove leuko-
cytes as described [17]. In KCS, samples were then frozen
as 0.5 mL filtered blood volumes on-site (Nairobi, Kenya)and transferred to KEMRI-Wellcome Trust, Centre for
Geographical Medical Research (Coast), Kilifi, Kenya for
further processing. For VAC052, blood filtration, DNA ex-
traction and qPCR were performed immediately on fresh
samples onsite (Oxford, UK) to allow same-day monitor-
ing. For the ‘standard volume’ qRT-PCR assay, 50 μL of
whole blood was aliquoted into 2 mL lysis buffer (bioMér-
ieux), which was then mixed and frozen onsite at −80°C as
described [14]. For qRT-PCR from DBS cards (KCS study
alone), 50 μL of EDTA-anticoagulated whole blood was
pipetted onto a standard DBS card (Whatman), which was
subsequently dried, desiccated and frozen onsite as de-
scribed [14]. ‘Large volume’ qRT-PCR samples were pre-
pared in duplicate by adding 0.5 mL whole blood to
20 mL lysis buffer (bioMérieux), after which the samples
were frozen onsite and stored as for the standard samples.
qRT-PCR samples were then transported on dry ice by
courier to UW as lysis buffer-preserved, frozen samples
(for standard and large volume aliquots) or as desiccated,
frozen DBS cards.DNA extraction and qPCR (Oxford protocol)
Briefly, DNA was extracted from 0.5 mL of filtered blood,
and 10% of the extracted DNA was used per qPCR reac-
tion (in triplicate) as previously reported [9]. Based upon
results obtained using a dilution series of microscopically
counted cultured parasites, this method has a LLQ,
(defined as the parasite density at which the assay
%CV <20%) of 20 p/mL. Counted parasite dilution series
results suggest that the LLD (i.e., a probability of >50%
of ≥1 positive result among three replicate PCR reactions)
is ~5 p/mL. Results were reported as ≥ LLQ when ≥20
p/mL and ≥ LLD when in the 5–19 p/mL range.Total nucleic acid extraction and qRT-PCR (UW protocol)
After storage at −80°C, standard volume liquid samples
were extracted as described [14]. DBS samples were laser
cut, incubated with 2 mL lysis buffer with continuous shak-
ing overnight and then the lysis buffer was transferred to
the m2000sp (Abbott Molecular, Inc). Large volume sam-
ples were completely thawed, and 1 mL of the 20.5 mL so-
lution was transferred to the m2000sp instrument for
extraction using the same parameters as for standard vol-
ume samples. Extraction and qRT-PCR for all specimens
were performed as previously reported [14] with the RNA
standard curve extended into the range corresponding to
1–20 p/mL. Standard volume and DBS samples were tested
in singlet while large volume samples were tested in dupli-
cate (2 × 0.5 mL = 1 mL sample). Results were reported for
standard volume and DBS samples to 20 p/mL (≥LLQ)
with ‘low positive below the LLQ’ reported in the 10–20
p/mL range (≥LLD). Large volume samples were reported
to a quantitative limit of 2 p/mL (≥LLQ) with ‘low positive
Table 1 Subject characteristics
Study VAC052 KCS






27 (19–45) 25 (19–31)
Sex 11 females, 21 males 11 females, 17 males
Site Centre for Clinical Vaccinology
& Tropical Medicine, Oxford,
UK
KEMRI Centre for Clinical
Research, Nairobi, KenyaStatistics and modelling
Results were converted to log10 p/mL and evaluated
using Microsoft Excel 2010 and GraphPad Prism 6.
Where more than one replicate at a given time-point
was available, the mean was used for analysis. For
VAC052, ‘clinical sensitivity’ at D7.5 was calculated as
‘true positives/(true positives + false negatives)’ and
‘clinical specificity’ as ‘true negatives/(true negatives +
false positive)’ using the study protocol-defined defini-
tions of malaria infection as the gold standard (NAA
et al., in preparation). The VAC052 study protocol-
defined definition of malaria infection included persons
meeting any one of the three following scenarios: 1) no
symptoms but with a positive TBS and at least one
sample qPCR positive >500 p/mL; 2) malaria-related
symptoms and a positive TBS; or, 3) malaria-related
symptoms, a negative TBS and a least one positive qPCR
result >500 p/mL. Vaccinees were defined as demon-
strating a ‘significant delay to diagnosis’ if the time to
diagnosis (TTD) was ≥2 × the standard deviation in
days after the mean TTD for unimmunized control
volunteers.
For KCS, ‘clinical sensitivity’ was calculated for the NAT
results at D6.5. In addition, ‘cumulative clinical sensitivity’
was also calculated using results obtained until D7.0 (i.e.,
D6.5-7.0) and until D7.5 (i.e., D6.5-7.5). The KCS study
protocol-defined definition of malaria infection was used as
the gold standard [15] and included persons meeting any
one of the three following scenarios: 1) no symptoms but
positive TBS; 2) malaria-related symptoms and a positive
TBS; or, 3) malaria-related symptoms and a negative TBS.
All results exceeding the LLD were used for all sensi-
tivity and specificity comparisons. Data ≥ LLQ for each
assay were assessed to determine correlation (using two-
tailed Spearman test) and were plotted using Bland-
Altman charts to determine quantitative bias.
Results were used to calculate LBI for individual vol-
unteers using the peak first-cycle parasitaemia method
(highest NAT value between D6.5-7.5 multiplied by the
blood volume (volunteer weight × 70 mL blood/kg) [11].
A value of 1.0 was added to all LBI values to allow log-
transformation of negative data points.Table 2 VAC052 sensitivity and specificity by assay for
values ≥ LLD
Diagnosis by method (blood volume) Sensitivity Specificity
UW large volume qRT-PCR (0.5 mL) 88.9% 100%
Oxford qPCR (0.5 mL) 70.4% 100%
UW standard qRT-PCR (0.05 mL) 74.1% 100%Results
Subject demographics
Samples were collected from 32 subjects in the VAC052
study and 28 subjects in the KCS study; demographics of
volunteers are shown in Table 1. In the KCS study, whilst all
volunteers were successfully infected, one volunteer demon-
strated control of parasitaemia and remained undiagnoseduntil D21 [15]; data from this volunteer was excluded from
sensitivity and specificity analyses.
Large volume assay accelerates early NAT diagnosis
Starting with samples from D7.5 in VAC052, Oxford qPCR
(0.5 mL DNA) and UW-based standard (0.05 mL RNA/
DNA) and large volume (0.5 mL RNA/DNA) qRT-PCR as-
says were performed to see if increasing the volume of
blood tested by qRT-PCR enhanced sensitivity. This sample
set included 32 persons, 27 of whom developed patent
parasitaemia by D21, five of whom did not develop malaria
infection by D21, and six of whom showed a significant
delay to diagnosis (NAA et al., in preparation). Of the 27
samples from subjects who became positive collected on
D7.5, 19/27 were positive (≥LLD) by Oxford qPCR, 20/27
by UW standard volume qRT-PCR and 24/27 by UW large
volume qRT-PCR. The only subjects negative by all assays
were those who either did not develop malaria infection
and three of six who showed a significant delay to diagnosis
as noted above. Overall ‘clinical sensitivity’ (see definition in
Methods) was 70.4% for the Oxford qPCR, 74.1% for the
UW-based standard volume qRT-PCR and 88.9% for the
large volume qRT-PCR assay; specificity for all assays was
100% (Table 2).
Since the larger volume RT-PCR assay showed in-
creased sensitivity at D7.5 in VAC052, the next step was
to test blood from 27 subjects sampled during the first
cycle of expected parasitaemia in the KCS trial (D6.5-7.5).
All 27 subjects included in the analysis developed positive
P. falciparum infections by TBS by the end of the trial
[15]. Since 100% of the subjects were positive by the gold
standard definition, specificity of the assays could not be
compared. The large volume qRT-PCR assay was most
sensitive in this dataset, followed by the Oxford qPCR, the
standard volume qRT-PCR and the dried blood spot
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volume qRT-PCR assay detected the highest number of
positive specimens (10/27), followed by the Oxford qPCR
(7/27) and the UW standard volume qRT-PCR assay (1/
27). Amongst samples positive on D6.5, all large volume
qRT-PCR (n = 10) and standard volume qRT-PCR assay
samples (n = 1) were quantifiable within the limits of the
assay (i.e., ≥LLQ), whereas all samples positive by Oxford
qPCR (n = 7) were in the ‘low positive’ range (i.e., ≥LLD).
By D7.0, most samples were qualitatively positive by all as-
says (27/27 by large volume qRT-PCR, 26/27 by Oxford
qPCR, 19/27 by standard volume qRT-PCR and 14/26
by DBS qRT-PCR), which increased further by D7.5. A
large proportion of samples tested by Oxford qPCR were
identified as ‘low positives’ (i.e., LLQ > result ≥ LLD) (27/
60 positive qPCRs on D6.5-D7.5) whereas this was less
common amongst qRT-PCR positive samples (0/61 large
volume qRT-PCR, 3/43 standard volume qRT-PCR, 5/35
DBS qRT-PCR). Finally, the large volume qRT-PCR and
the Oxford qPCR assays became positive (≥LLD) on average
on D7.0 compared to D12.5 by microscopy (Figure 1), a
5.5-day lead time over microscopy.
Comparison of parasite densities determined by different
assays
Next, an inter-assay comparison of quantitative results
was performed. All tests that generated results ≥ LLQ
were included. With the exception of the pairing of
Oxford qPCR results with DBS qRT-PCR results, all
datasets showed statistically significant concentration-
dependent correlation with one another (Figure 2). The
strongest correlation was between large and standard
volume qRT-PCR assays. While Oxford and UW assays
showed strong correlation, when comparisons were
made using Bland-Altman plots to look for quantitative
agreement and bias, a consistent quantitative shift be-
tween centers was observed (Figure 3), consistent with a
previous report showing qualitative agreement of the
Oxford data with that of other CHMI centers including
UW, but a consistent quantitative shift at Oxford due to
blood filtration and calibration differences [5]. DBS qRT-
PCR results also diverged from UW liquid results, and
this shift resulted in apparent alignment between Oxford
qPCR and UW DBS qRT-PCR results.Table 3 KCS sensitivity by assay for values ≥ LLD
Diagnosis by method (blood volume)* D6.5 D7.0 D7.5
UW large volume qRT-PCR (0.5 mL) 37.0% 100.0% 100.0%
Oxford qPCR (0.5 mL) 25.9% 96.3% 100.0%
UW standard qRT-PCR (0.05 mL) 3.7% 70.4% 88.9%
UW DBS qRT-PCR (0.05 mL) 0.0% 50.0% 84.6%
n = 27 (n = 26 DBS)
*KCS malaria diagnosis definition by D21 as the gold standard comparator.Effects of assay sensitivity on estimation of LBI and
prediction of outcome
In VAC052, the purpose of the study was to assess the
efficacy of novel vaccines targeting the pre-erythrocytic
infection, a surrogate of which is LBI. A comparison was
undertaken of LBI estimated from the maximum qPCR
value obtained with Oxford qPCR between D6.5 and
D7.5 (four data-points: D6.5, D7.1, D7.3, D7.5; the first
cycle peak method [11]) and the UW large volume qRT-
PCR result at D7.5 only. Sterilely-protected volunteers
were NAT negative by all assays and were excluded from
analysis. Comparison of the ability to calculate LBI using
different datasets is shown in Table 4. Although LBI
could be estimated for 81% of participants (n = 21) using
Oxford qPCR data ≥ LLD, LBI could only be quantified
using Oxford qPCR data ≥ LLQ for 67% of participants
(n = 18). LBI could be quantified using UW qRT-PCR
data ≥ LLQ in 85% of participants (n = 23).
In the KCS study, LBI for the study publication was
calculated with simple linear regression using Oxford
qPCR values [15] but could not be calculated with sim-
ple linear regression using qRT-PCR data since samples
were taken at only three first-cycle timepoints. For the
purposes of comparison, LBI was therefore estimated
here with the first cycle peak method using Oxford
qPCR data ≥ LLQ and ≥ LLD and large volume RT-PCR
data ≥ LLQ (Table 5). Use of qRT-PCR increased the
proportion of KCS volunteers for whom LBI could be
calculated more accurately using data > LLQ (Table 4).
Discussion
In this study, an ultrasensitive P. falciparum 18S rRNA
qRT-PCR was tested to determine if this approach could
provide earlier and more quantitative data for CHMI
modelling. The samples tested were from timepoints
(D6.5-7.5) that coincide with the release of erythrocyte-
stage parasites from the liver. During this early period,
the absolute number of blood-stage parasites in a person
following standard CHMI is extremely low (e.g., ~3×105
erythrocyte-stage parasites emanating from ~14 infected
hepatocytes based on [17-20] and likely lower with par-
tial liver-stage efficacy of vaccine or drug treatments
or with reduced sporozoite inoculum). Given the ~5 L
blood volume of a 70 kg adult, the number of parasites
estimated to be released by a single infected hepatocyte
(~20,000) will result in a peak parasitaemia of ~4 p/mL
in the first cycle. This level is not reliably detectable or
quantifiable using previously described NATs. Moreover,
parasite egress from the liver does not happen all at
once and instead infected hepatocytes likely release
merosomes more gradually starting on D5-6 [12,13]. As
such, while assays capable of detecting 20 p/mL may
detect all infected persons by the time that release from
the liver is complete (e.g., D7.5), more sensitive assays
Figure 1 Time to positivity for microscopy, Oxford qPCR and large
volume qRT-PCR in KCS. Kaplan-Meier survival curve representing the
rate of conversion from negative to positive NAT results by test method
(>=LLQ). Solid line, UW large volume qRT-PCR; heavy dashed line, Oxford
qPCR; light dotted line, microscopy diagnosis.
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start of the erythrocytic stage.
The UW large volume qRT-PCR assay accelerated early
malaria diagnosis compared to other assays. If the large vol-
ume qRT-PCR was applied at all pre-diagnosis timepoints
post-CHMI, it is likely that the increased sensitivity could
speed diagnosis if used in real time as a criterion to initiate
treatment in CHMI studies assessing pre-erythrocytic drugs
and vaccines. Data generated from such an approach couldFigure 2 Correlation analyses. Data were compiled from all samples in b
results were plotted as shown; Spearman rank correlation (R); two-tailed p v
for paired samples by the methods listed on each axis.improve the accuracy of LBI estimation in those trials
where early timepoints (up to D7.5) were frequently nega-
tive by standard assays [8,9]. In studies where early time-
points are qualitatively positive by Oxford qPCR or
standard UW qRT-PCR, the large volume qRT-PCR could
improve the accuracy of absolute LBI albeit at an increased
reagent cost. However, given variability in the challenge in-
ocula used in mosquito sporozoite CHMI studies, analyses
are usually restricted to intra- not inter-study data, so the
absolute qPCR or qRT-PCR (and calculated LBI) values are
not as critical for comparisons between studies. If there is a
move toward more CHMI trials using highly standardized
inocula (e.g., injection of PfSPZ Challenge [3]), then it may
be possible to perform inter-trial comparisons where use of
the more sensitive large volume qRT-PCR method at mul-
tiple sites could be especially useful. Ultrasensitive diagnosis
using this type of approach could also be useful in studies
of Duffy-negative subjects challenged with large numbers
of Plasmodium vivax-infected mosquitoes since these sub-
jects do not develop patent parasitaemia but can have de-
tectable parasite nucleic acids in their blood following
successful liver-stage development and abortive erythrocyte
infection (S. Herrera, pers. comm.). A deterrent to using the
large volume qRT-PCR as performed here is the cost of
the 20 mL of lysis buffer used to stabilize each 0.5 mL
blood sample. Ongoing studies suggest 18S rRNA from
0.5-1.0 mL of blood can be protected from degradation by
storage in 2 mL of lysis buffer provided that a sub-aliquototh clinical trials where two methods produced results≥ LLQ. Paired
alue. Units for x and y axes are log10 p/mL whole blood as determined
Figure 3 Agreement analyses. Data were compiled from all samples in both clinical trials where two methods produced results≥ LLQ and
plotted using a Bland-Altman (difference) chart showing the average result (x-axis) and the difference between results (y-axis) for each sample.
The labels indicate the mathematical order used to calculate difference. Units for x- and y-axes are log10 p/mL whole blood as determined for
paired samples by the methods listed on graph. The average difference from a value of 0.0 log10 p/mL equals the bias.
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(1.75 mL) once thawed for extraction to maintain a stan-
dardized blood-to-lysis buffer ratio, although additional
studies are required to confirm stability during storage and
transport (SCM, pers. comm.). The above observations
were made using quantitative data ≥ LLQ for each assay.
When the LBI was calculated using all data (including data
inferred on samples below the LLQ but ≥ LLD), there wereTable 4 Comparison of ability to estimate liver to blood inocu
and KCS: qRT-PCR vs Oxford qPCR methods








using data ≥ LLQ
18 (67%)
Not able to estimate







using data ≥ LLQ
20 (71%)
Not able to estimate
using data ≥ LLQ
0
Sterilely protected VAC052 volunteers were NAT negative by all assays and were exminimal differences between the proportions of individuals
with positive LBI calculated using the large volume qRT-
PCR and the Oxford qPCR approaches. Thus, while prefer-
able to use most accurate data (i.e., ≥LLQ), given the added
cost of the large volume qRT-PCR sample stabilization, it
may be suitable to use standard qPCR or qRT-PCR
methods and include values < LLQ but ≥ LLD when calcu-




Not able to estimate
using data≥ LLQ
Not able to estimate
using data≥ LLD
22 (81%) 5 (19%) 1 (4%)
1 (4%) 4 (15%) 3 (11%)
28 (100%) 8 (29%) 0
0 0 0
cluded from the analysis.
Table 5 Estimations of liver to blood inoculum (LBI) for
KCS study
LBI Peak method*
≥ LLQ ≥ LLD
Min Max Min Max
Oxford qPCR 97,608** 1,396,941** 33,768 1,396,941
UW large volume qRT-PCR 37,800 1,855,630 37,800 1,855,630
*Units are total number of parasites estimated to be released from the liver.
**n = 20 (8 volunteers had negative LBI). All other analyses n = 28.
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between assays, all methods generated data with a high
degree of concentration-dependent correlation. The liquid-
based assays at UW had the highest degree of quantitative
agreement by Bland-Altman analyses, while the Oxford
qPCR showed a consistent quantitative shift between
Oxford qPCR and both liquid sample-based UW qRT-PCR
assays. This quantitative shift was likely due to loss of
parasites during Oxford filtering of whole blood and to
differences in the matrix used for plasmid DNA calibrators
at Oxford, as reported [5]. The UW DBS qRT-PCR also
diverged from the UW liquid-based samples, likely due to
incomplete recovery of the target from the DBS surface
[14]. The apparent alignment between Oxford qPCR and
UW DBS qRT-PCR results is likely due to losses in both
assays but this alignment should not be used to consider
the assays equivalent as both centers are working to reduce
such losses to align these assays with the liquid qRT-PCR
results (SCM, pers. comm.).
The factors that limit the ability of DNA-based qPCR
versus total nucleic acid-based qRT-PCR to achieve in-
creased sensitivity vary as follows. Since the Oxford qPCR
detects relatively few 18S rDNA copies per parasite, this
assay requires a PCR that can detect just a few copies of
the 18S rDNA per reaction [9]. While single copy detec-
tion is achieved in some HIV-1 NATs [21,22], detection of
any molecular target at one to 20 copies per reaction gen-
erally occurs beyond 40 cycles of PCR (or RT-PCR), which
is nearing the performance limits for most assays. For the
Oxford qPCR, the LLD is reached at ~41 PCR cycles. As
such, in the Oxford qPCR, the relatively few target se-
quences present dictate the LLD. For the UW qRT-PCR
[14], ~3,500 18S rRNA copies are detectable in each ring-
stage parasite. Thus, at the published LLD for the UW
qRT-PCR assay, when a single parasite is present in
0.05 mL of whole blood, there are 3,500 copies of the 18S
rRNA target that are detected at ~33.5 cycles. Thus, in
qRT-PCR, the LLD is dictated by whether or not a single
intact parasite is present in the sampled blood volume – if
a single parasite is present then the 18S rRNA load for
even one parasite is readily detectable.
In this study, qRT-PCR was also performed on whole
blood preserved on DBS cards. While the quantitative DBS
data showed some target loss compared to liquid samplesresulting in the lowest overall sensitivity between methods
across all sampling days, sensitivity on D7.5 (84.6%) was
comparable to standard qRT-PCR (88.9%) indicating that
DBS-based qRT-PCR is suitable for pre-patent diagnosis
well ahead of microscopic diagnosis. These samples were
collected and initially stored in a field setting with the use
of desiccant and humidity indicators and then were shipped
to the UW testing facility, where they were processed by
laser cutting and qRT-PCR. For studies where early (D6.5-
7.5) diagnosis is not as critical, DBS qRT-PCR for malaria
may offer an attractive option for field studies since the
samples are conveniently collected, stored and shipped.
In summary, this report demonstrates that qPCR and
qRT-PCR methods with analytical sensitivities of ~20 p/mL
are sufficient for most CHMI purposes. At timepoints when
directly calculated LBI is desired, an ultrasensitive large
volume qRT-PCR may be most useful.
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